Comparison 1. Tafenoquine (TQ) 300 mg single dose versus no hypnozoite treatment (chloroquine (CQ)).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Recurrent P vivax parasitaemia by 6 months (intention to treat)	2	504	Risk Ratio (M‐H, Random, 95% CI)	0.32 [0.12, 0.88]
1.2 Serious adverse events	2	504	Risk Ratio (M‐H, Fixed, 95% CI)	1.34 [0.63, 2.84]
1.3 Adverse events by type	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.3.1 Any adverse event	2	504	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.81, 1.13]
1.3.2 Abdominal pain	2	504	Risk Ratio (M‐H, Fixed, 95% CI)	0.66 [0.33, 1.33]
1.3.3 Nausea	2	504	Risk Ratio (M‐H, Fixed, 95% CI)	1.05 [0.53, 2.07]
1.3.4 Vomiting	2	504	Risk Ratio (M‐H, Fixed, 95% CI)	1.29 [0.57, 2.93]
1.3.5 Diarrhoea	2	504	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.42, 2.50]
1.3.6 Vertigo/dizziness	2	504	Risk Ratio (M‐H, Fixed, 95% CI)	1.89 [0.88, 4.08]
1.3.7 Headache	2	504	Risk Ratio (M‐H, Fixed, 95% CI)	0.55 [0.33, 0.92]
1.3.8 Rash/pruritus	2	504	Risk Ratio (M‐H, Fixed, 95% CI)	0.92 [0.57, 1.50]
1.3.9 QT prolongation	2	504	Risk Ratio (M‐H, Fixed, 95% CI)	0.37 [0.12, 1.20]
1.3.10 Anaemia/drop in haemoglobin	2	504	Risk Ratio (M‐H, Fixed, 95% CI)	2.84 [0.80, 10.09]
1.4 Recurrent P vivax parasitaemia by 6 months (per protocol)	2	408	Risk Ratio (M‐H, Random, 95% CI)	0.31 [0.13, 0.77]
1.5 Recurrent P vivax parasitaemia by 6 months (worst‐case scenario)	2	504	Risk Ratio (M‐H, Random, 95% CI)	0.36 [0.14, 0.90]
1.6 Recurrent P vivax parasitaemia by region – Asia	2	130	Risk Ratio (M‐H, Fixed, 95% CI)	0.44 [0.28, 0.69]
1.7 Recurrent P vivax parasitaemia by region – Africa	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.38 [0.16, 0.87]
1.8 Recurrent P vivax parasitaemia by region – South America	2	332	Risk Ratio (M‐H, Fixed, 95% CI)	0.43 [0.34, 0.55]